This is a summary of the European public assessment report (EPAR) for Kyntheum. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kyntheum. For practical information about using Kyntheum, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L04AC12
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
EMA Name
Kyntheum
Medicine Name
Kyntheum
Aliases
N/ANo risk management plan link.
